AI Tool Shows Promise for Assessing Pathologic Response in Lung Cancer Treatment

https://www.medscape.com/viewarticle/ai-tool-shows-promise-assessing-pathologic-response-lung-2026a1000xme?src= An AI algorithm achieved 91% accuracy in assessing pathologic response (PR) to neoadjuvant chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC), with performance consistent across four international cohorts. The AI-based percentage of residual viable tumour (%RVT) scoring showed at least moderate concordance with expert pathologist consensus, and discordant classifications occurred in fewer than 9% of cases.